BG Medicine, a molecular diagnostics firm in Waltham, MA, announced today that it has closed a Series D financing round worth $40 million. Legg Mason Capital Management, GE Asset Management, and SMALLCAP World Fund, participated, as did existing investors Flagship Ventures, Gilde Healthcare Partners, Humana, Stelios Papadopoulos. BG pulled a planned IPO back in January; it says it will use the new private funding to help it bring its first two biomarker-based diagnostic tools to market.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
